Exagen Diagnostics, Inc., a leading medical diagnostic company focused in rheumatology, recently announced the addition of the Avise SLE Prognostic panel to its testing services.
Clinigene Launches a Best-in-class Biomarker Assay for Measuring “ABCA1 Specific Cholesterol Efflux”
Clinigene International Ltd, a subsidiary of Syngene International Ltd, India’s leading Contract Research Services provider, today announced that it has launched a cholesterol efflux assay to support global aspirants developing cholesterol lowering drugs. This biomarker assay is a cell based assay for assessing the ATP-binding cassette A1 (ABCA1) specific cholesterol efflux capacity in human serum samples.
Ventana Medical Systems, Inc. and MedImmune Collaborate to Develop a Custom PD-L1 Assay for Immunotherapy Clinical Trials
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group and MedImmune, the global biologics research and development arm of AstraZeneca, recently announced they are jointly developing a PD-L1 (SP263) immunohistochemistry assay to enroll patients in clinical trials for MedImmune’s MEDI4736 anti-PD-L1 therapy for non-small cell lung carcinoma. This includes the recently commenced MEDI4736 ATLANTIC trial that will enroll only patients who express PD-L1 as determined by the VENTANA assay.
Amgen Joins The National Cancer Institute And Research Partners To Help Accelerate Development Of Personalized Treatment Approaches For Squamous Cell Lung Cancer
Amgen (NASDAQ:AMGN) recently announced that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP), a groundbreaking new clinical trial program that will use biomarker-driven research and genomic profiling to match squamous cell lung cancer patients to investigational treatments based on their individual cancer profiles. Lung-MAP is the first trial of its kind to study a large number of rare lung cancer subsets under one trial protocol.
EUTROPICS Inc., a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, recently announced its laboratory, located in Cambridge, MA, has received Clinical Laboratory Improvement Amendment (CLIA) certification from the U.S. Department of Health and Human Services’ Centers for Medicare and Medicaid Services (CMS) for its clinical diagnostics laboratory in Cambridge, Massachusetts. This certification follows receipt of a Massachusetts State license and allows the company to accept clinical samples from most U.S. states. The Milestone Clears the Path to Launch of PraediCare-Dx(TM).